Faculty Research 1980 - 1989
Tumor radioimmunolocation: differential antibody retention by antigenic normal tissue and tumor.
Document Type
Article
Publication Date
1984
Keywords
Antibodies-Monoclonal: im, Antibody-Affinity, Antigens-Neoplasm: an, im, Antigens-Surface: an, im, Brain: im, Glycolipids: an, im, Kidney: im, Liver: im, Mice, Salivary-Glands: im, SUPPORT-U-S-GOVT-NON-P-H-S, SUPPORT-U-S-GOVT-P-H-S, Teratoma: im
First Page
2111
Last Page
2116
JAX Source
J Immunol 1984 Apr;132(4):2111-6
Grant
CA31784, HD12487
Abstract
On the assumption that a high specificity would be required for in vivo tumor location and drug targeting, much labor has been expended to produce monoclonal antibodies directed to antigens found primarily on tumors. However, for at least one tumor-associated antigen, stage-specific embryonic antigen 1 (SSEA-1), the concentration of the target antigen need not be higher in the tumor than that found in normal tissues for successful use of the corresponding monoclonal antibody in in vivo tumor location; rather, accessibility and antibody metabolism are more important.
Recommended Citation
Ballou B,
Jaffe R,
Taylor RJ,
Solter D,
Hakala TR.
Tumor radioimmunolocation: differential antibody retention by antigenic normal tissue and tumor. J Immunol 1984 Apr;132(4):2111-6